EN | CN

Highlight BD-Focused Sessions at BIOCHINA 2026

18 December 2025

From Q1–Q3 2025, China-originated pharma license-out deals reached USD 92.03 billion, up 77% YoY, with upfront payments of USD 4.55 billion.

Leading multinational pharma sourced 20% of global in-licensing deals from China, accounting for 39% of total deal value. Nearly 40% of global payments flowed to Chinese innovators.

As BD strategy drives cross-border innovation and growth, where will global BD leaders be at BIOCHINA 2026?


1. BIOCHINA 2026 Main Forum

Strategic Insights from Global Pharma Leaders

09:00–11:00 | MNC Strategy Release

11:00–12:00 | Co-Creating a Collaborative Ecosystem with Global Partners

Speakers:

Faisal Darwazeh, Vice President, Group Business Development & Alliances, Hikma Pharmaceuticals

Albert Ren, Vice President, Worldwide Business Development China, Pfizer

Ryan Wang, Vice President, China Innovation & Partnerships, Eli Lilly


2. BIOCHINA 2026 BioBD Forum

Date: March 12, 2026

12:00–12:20 | Presentation: Insights on BD Deals for Chinese Innovative Drugs and Global Enablement

12:20–13:10 | Presentation: MNC Asia-Pacific Strategy

13:10–14:00 | Presentation: Global Strategies of Chinese Big Pharma and Biotech

15:00–16:00 | Presentation: NewCo Evolution and MNC–China Collaboration

16:00–17:00 | Presentation: Global Expansion: China’s Innovation Pathways

17:00–18:00 | Presentation: Breaking Through Payment Barriers for Innovative Drugs

Speakers:

Jean-Baptiste Duval, Director, Healthcare and Life Sciences, the cfi group

Yulan Feng, General Manager, Business Development, Fosun Pharma

Mingji Chen, Chairman and Chief Executive Officer, Biosion Biotech

Tongtong Xue, Chief Executive Officer, MediLink Therapeutics

Hua Jiang, Chairwoman and Chief Executive Officer, Boan Biotech

Jiang Zhang, Founder and Chief Executive Officer, LongRiver Investments

 

Download Agenda https://static.biocn.cn/file/BIOCHINA2026_Agenda_1209.pdf

To join the forum as a speaker, contact biochina@enmore.com

 

3. BiOPartnering2026 High-Quality Networking at BIOCHINA

Connect with global pharma leaders, explore collaboration opportunities, and meet potential partners in focused 30-minute 1V1 meetings. Engage with innovative companies and accelerate your business growth.

 

Early Bird Register (Ends Dec 31) https://u.morebio.cn/mABz6jLG

For promo code registration, please contact biochina@enmore.com

Learn More https://static.biocn.cn/file/BiOPartnering.pdf